Bluejay Diagnostics, Inc. BJDX
We take great care to ensure that the data presented and summarized in this overview for Bluejay Diagnostics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BJDX
Top Purchases
Top Sells
About BJDX
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Insider Transactions at BJDX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2023
|
Indranil Dey President and CEO |
BUY
Open market or private purchase
|
Direct |
500
+1.72%
|
$1,500
$3.27 P/Share
|
|
Dec 13
2023
|
Svetlana Dey Director |
BUY
Open market or private purchase
|
Direct |
500
+25.0%
|
$1,500
$3.07 P/Share
|
|
Mar 28
2023
|
Indranil Dey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+0.3%
|
$0
$0.44 P/Share
|
|
Mar 27
2023
|
Indranil Dey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+1.41%
|
$0
$0.44 P/Share
|
|
Mar 24
2023
|
Svetlana Dey Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+17.39%
|
$0
$0.44 P/Share
|
|
Feb 01
2023
|
Gary G Gemignani Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+50.0%
|
$0
$0.44 P/Share
|
|
Feb 01
2023
|
Svetlana Dey Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+42.31%
|
$0
$0.44 P/Share
|
|
Feb 01
2023
|
Donald R Chase Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+3.35%
|
$0
$0.44 P/Share
|
|
Feb 01
2023
|
Kenneth R Fisher Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
39,316
-25.78%
|
$0
$0.44 P/Share
|
|
Feb 01
2023
|
Kenneth R Fisher Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,500
+42.45%
|
$0
$0.44 P/Share
|
|
Feb 01
2023
|
Indranil Dey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
55,612
-9.17%
|
$0
$0.44 P/Share
|
|
Feb 01
2023
|
Indranil Dey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
159,090
+20.79%
|
$0
$0.44 P/Share
|
|
Feb 01
2023
|
Douglas Clark Wurth Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+1.17%
|
$0
$0.44 P/Share
|
|
Feb 01
2023
|
Fred S Zeidman Director |
BUY
Grant, award, or other acquisition
|
Direct |
27,500
+50.0%
|
$0
$0.44 P/Share
|
|
Aug 26
2022
|
Kenneth R Fisher Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+33.33%
|
$20,000
$1.03 P/Share
|
|
Apr 25
2022
|
Kenneth R Fisher Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$0
$0.99 P/Share
|
|
Mar 17
2022
|
Svetlana Dey Director |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$10,000
$1.18 P/Share
|
|
Mar 17
2022
|
Gordon Winston Kinder Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+11.9%
|
$2,500
$1.16 P/Share
|
|
Mar 17
2022
|
Douglas Clark Wurth Director |
BUY
Open market or private purchase
|
Direct |
40,000
+1.72%
|
$40,000
$1.18 P/Share
|
|
Mar 16
2022
|
Douglas Clark Wurth Director |
BUY
Open market or private purchase
|
Direct |
60,000
+2.6%
|
$60,000
$1.09 P/Share
|